NORRIS MEDICINES LTD. - 524414 - Shareholding for the Period Ended December 31, 2021
Norris Medicines Ltd has submitted to BSE the Shareholding Pattern for the Period Ended December 31, 2021. For more details, kindly Click here13-01-2022
13-01-2022
NORRIS MEDICINES LTD. - 524414 - Statement Of Investor Complaints For The Quarter Ended December 2021
No.of Investor complaints pending at the beginning of the quarter No.of Investor complaints received during the quarter No.of Investor complaints disposed of during the quarter No.of Investor complaints unresolved at the end of the quarter 0000 Name of the Signatory :- VINAY RANADesignation :- Company Secretary and Compliance Officer06-01-2022
NORRIS MEDICINES LTD. - 524414 - Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
With Reference to the subject matter, please find enclosed a certificate under Regulation 74 (5) of SEBI (Depositories and Participants) Regulations, 2018 for the period 1st October,2021 to 31st December, 2021, received from M/s. PurvaSharegistry (I) Pvt. Ltd., Registrar and Share Transfer Agent of our Company.06-01-2022
NORRIS MEDICINES LTD. - 524414 - Closure of Trading Window
This is to inform you that, as per the Company''s Code of Internal Procedures and Conduct for Regulating, Monitoring and Reporting of Trading by Insiders framed pursuant to the Security and Exchange Board of India (Prohibition of Insider Trading) Regulations, 2018, as amended, read with BSE circular no. LIST/COMP/O1/2019-20 dated 2nd April, 2019 regarding trading restriction period, the Trading Window for dealing in the Securities of the Company shall remain closed for the purpose of declaration of Unaudited Financial Results of the Company for the Quarter and Nine Months ended on 31st December, 2021 for all the designated persons of the Company from 01st January, 2022 to till 48 hours after the announcement of the Unaudited Financial Results of the Company to the Stock Exchanges.31-12-2021
Norris Medicines Ltd - 524414 - Submission Of Standalone Unaudited Financial Results In Compliance With Regulation 33 Of SEBI (LODR) Regulations, 2015
Dear Sir, Pursuant to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we submit herewith the following: 1) Standalone Unaudited Financial Results of the Company for the Quarter ended on 30th September, 2021. 2) Limited Review Report on Standalone Unaudited Financial Results for the quarter ended on 30th September, 2021.12-11-2021
NORRIS MEDICINES LTD. - 524414 - Board Meeting Outcome for Outcome Of Board Meeting
The Board of directors of the Company on its meeting held on today i.e 12.11.2021 has considered and approved: 1) Standalone Unaudited Financial Results of the Company for the Quarter ended on 30th September, 2021. 2) Limited Review Report by Statutory Auditors on Standalone Unaudited Financial Results for the quarter ended on 30th September, 2021. The Board has also discussed the other operational, financial and administrative matters in details and passed the necessary resolutions.12-11-2021
NORRIS MEDICINES LTD. - 524414 - Board Meeting Intimation for Approval Of Unaudited Standalone Financial Results Of The Company For The Quarter Ended On 30Th September, 2021.
NORRIS MEDICINES LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 12/11/2021 ,inter alia, to consider and approve Unaudited Standalone Financial Results of the Company for the Quarter ended on 30th September, 202130-10-2021
NORRIS MEDICINES LTD. - 524414 - Shareholding for the Period Ended September 30, 2021
Norris Medicines Ltd has submitted to BSE the Shareholding Pattern for the Period Ended September 30, 2021. For more details, kindly Click here20-10-2021
NORRIS MEDICINES LTD. - 524414 - Statement Of Investor Complaints For The Quarter Ended September 2021
No.of Investor complaints pending at the beginning of the quarter No.of Investor complaints received during the quarter No.of Investor complaints disposed of during the quarter No.of Investor complaints unresolved at the end of the quarter 0000 Name of the Signatory :- VINAY RANADesignation :- Company Secretary and Compliance Officer04-10-2021
NORRIS MEDICINES LTD. - 524414 - Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
With Reference to the subject matter, please find enclosed a certificate under Regulation 74 (5) of SEBI (Depositories and Participants) Regulations, 2018 for the period 1st July,2021 to 30th September, 2021, received from M/s. Purva Sharegistry (I) Pvt. Ltd., Registrar and Share Transfer Agent of our Company04-10-2021